Joshua H. Bilenker Sells 7,500 Shares of Loxo Oncology, Inc. (LOXO) Stock

Loxo Oncology, Inc. (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $73.73, for a total value of $552,975.00. Following the completion of the sale, the chief executive officer now owns 196,207 shares in the company, valued at approximately $14,466,342.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Loxo Oncology, Inc. (NASDAQ LOXO) opened at 71.50 on Friday. The stock’s 50 day moving average price is $74.35 and its 200-day moving average price is $55.81. The company’s market cap is $2.13 billion. Loxo Oncology, Inc. has a 52 week low of $17.14 and a 52 week high of $83.12.

Loxo Oncology (NASDAQ:LOXO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by $0.15. During the same quarter in the prior year, the firm earned ($0.77) earnings per share. Analysts expect that Loxo Oncology, Inc. will post ($4.34) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/08/18/joshua-h-bilenker-sells-7500-shares-of-loxo-oncology-inc-loxo-stock.html.

Several research firms have commented on LOXO. Morgan Stanley restated an “overweight” rating and issued a $91.00 target price on shares of Loxo Oncology in a research note on Monday, June 19th. BidaskClub upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 target price on the stock in a research note on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and issued a $94.00 target price (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. Finally, BTIG Research restated a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $79.67.

Several hedge funds and other institutional investors have recently made changes to their positions in LOXO. State Street Corp boosted its position in shares of Loxo Oncology by 2.1% in the fourth quarter. State Street Corp now owns 214,321 shares of the biopharmaceutical company’s stock valued at $6,882,000 after buying an additional 4,360 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 905 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in shares of Loxo Oncology by 28.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 103,000 shares of the biopharmaceutical company’s stock valued at $4,334,000 after buying an additional 23,000 shares during the last quarter. Nationwide Fund Advisors boosted its position in shares of Loxo Oncology by 31.9% in the first quarter. Nationwide Fund Advisors now owns 27,434 shares of the biopharmaceutical company’s stock valued at $1,154,000 after buying an additional 6,632 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Loxo Oncology by 33.3% in the first quarter. Wells Fargo & Company MN now owns 15,503 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 3,875 shares during the last quarter.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit